Literature DB >> 18651319

Cholesterol content drives distinct pharmacological behaviours of micro-opioid receptor in different microdomains of the CHO plasma membrane.

G Gaibelet1, C Millot, C Lebrun, S Ravault, A Sauliere, A Andre, B Lagane, A Lopez.   

Abstract

Cholesterol in the plasma membrane of eukaryotic cells contributes to modulating the functions and signalling pathways of numerous transmembrane proteins, including G protein Coupled Receptors (GPCRs). We have previously shown that the function of the human micro-opioid receptor (hMOR) expressed in Saccharomyces cerevisiae is modulated by sterols including cholesterol. Here, we investigated the effects of cholesterol content on hMOR pharmacology and on hMOR partitioning in cholesterol-poor and -rich domains in eukaryotic mammalian cells (CHO). We show that cholesterol is required for the stabilization of a receptor conformation with high agonist affinity and for triggering G-protein activation after agonist binding to the receptor. Biochemical analysis of untreated and cholesterol-depleted membranes in cells expressing hMOR indicated that the receptor is only present in cholesterol poor domains, in the basal state. After agonist binding to untreated CHO membranes, two distinct populations of receptor were found in cholesterol-rich and -poor domains. Cholesterol depletion or treatment of CHO membranes with the G-protein-decoupling agent GppNHp prevented the redistribution, indicating that receptor activated states localized into cholesterol-rich domains. Pharmacological data and biochemical analysis indicate that distinct activated conformations of hMOR exist in CHO plasma membrane and correspond to microdomains differing by thickness and proportions of lipid components, including cholesterol.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18651319     DOI: 10.1080/09687680802203380

Source DB:  PubMed          Journal:  Mol Membr Biol        ISSN: 0968-7688            Impact factor:   2.857


  10 in total

Review 1.  Membrane functional organisation and dynamic of mu-opioid receptors.

Authors:  André Lopez; Laurence Salomé
Journal:  Cell Mol Life Sci       Date:  2009-03-20       Impact factor: 9.261

2.  Agonist-selective dynamic compartmentalization of human Mu opioid receptor as revealed by resolutive FRAP analysis.

Authors:  Aude Saulière-Nzeh Ndong; Aude Ndong Saulière-Nzeh; Claire Millot; Maithé Corbani; Serge Mazères; André Lopez; Laurence Salomé
Journal:  J Biol Chem       Date:  2010-03-02       Impact factor: 5.157

3.  Biased μ-opioid receptor agonists diversely regulate lateral mobility and functional coupling of the receptor to its cognate G proteins.

Authors:  Barbora Melkes; Lucie Hejnova; Jiri Novotny
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-06       Impact factor: 3.000

4.  GPCR stabilization using the bicelle-like architecture of mixed sterol-detergent micelles.

Authors:  Aaron A Thompson; Jeffrey J Liu; Eugene Chun; Daniel Wacker; Huixian Wu; Vadim Cherezov; Raymond C Stevens
Journal:  Methods       Date:  2011-10-21       Impact factor: 3.608

5.  Functional expression of opioid receptors and other human GPCRs in yeast engineered to produce human sterols.

Authors:  Björn D M Bean; Colleen J Mulvihill; Riddhiman K Garge; Daniel R Boutz; Olivier Rousseau; Brendan M Floyd; William Cheney; Elizabeth C Gardner; Andrew D Ellington; Edward M Marcotte; Jimmy D Gollihar; Malcolm Whiteway; Vincent J J Martin
Journal:  Nat Commun       Date:  2022-05-24       Impact factor: 17.694

Review 6.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

7.  Differential effect of membrane cholesterol removal on mu- and delta-opioid receptors: a parallel comparison of acute and chronic signaling to adenylyl cyclase.

Authors:  Erica S Levitt; Mary J Clark; Paul M Jenkins; Jeffrey R Martens; John R Traynor
Journal:  J Biol Chem       Date:  2009-06-11       Impact factor: 5.157

8.  GRK Mediates μ-Opioid Receptor Plasma Membrane Reorganization.

Authors:  Arisbel B Gondin; Michelle L Halls; Meritxell Canals; Stephen J Briddon
Journal:  Front Mol Neurosci       Date:  2019-05-01       Impact factor: 5.639

9.  Opioid doses required for pain management in lung cancer patients with different cholesterol levels: negative correlation between opioid doses and cholesterol levels.

Authors:  Zhenhua Huang; Lining Liang; Lingyu Li; Miao Xu; Xiang Li; Hao Sun; Songwei He; Lilong Lin; Yixin Zhang; Yancheng Song; Man Yang; Yuling Luo; Horace H Loh; Ping-Yee Law; Dayong Zheng; Hui Zheng
Journal:  Lipids Health Dis       Date:  2016-03-08       Impact factor: 3.876

10.  Impact of Lipid Composition and Receptor Conformation on the Spatio-temporal Organization of μ-Opioid Receptors in a Multi-component Plasma Membrane Model.

Authors:  Kristen A Marino; Diego Prada-Gracia; Davide Provasi; Marta Filizola
Journal:  PLoS Comput Biol       Date:  2016-12-13       Impact factor: 4.475

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.